Patents by Inventor Shyamala Maheswaran

Shyamala Maheswaran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Digital Analysis of Circulating Tumor Cells in Blood Samples
    Publication number: 20240132969
    Abstract: This disclosure relates to new assay methods for analysis of circulating tumor cells (CTCs) in blood samples for detection, e.g., early detection, and/or monitoring of disease, e.g., cancer. The methods provide ultra-high sensitivity and specificity, and include the use of microfluidic isolation of CTCs and digital detection of RNA derived from the CTCs.
    Type: Application
    Filed: December 26, 2023
    Publication date: April 25, 2024
    Inventors: Daniel A. Haber, Ravi Kapur, Mehmet Toner, Shyamala Maheswaran, Xin Hong, David Tomoaki Miyamoto, Tanya Todorova, Sarah Javaid
  • Digital analysis of circulating tumor cells in blood samples
    Patent number: 11898209
    Abstract: This disclosure relates to new assay methods for analysis of circulating tumor cells (CTCs) in blood samples for detection, e.g., early detection, and/or monitoring of disease, e.g., cancer. The methods provide ultra-high sensitivity and specificity, and include the use of microfluidic isolation of CTCs and digital detection of RNA derived from the CTCs.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: February 13, 2024
    Assignee: The General Hospital Corporation
    Inventors: Daniel A. Haber, Ravi Kapur, Mehmet Toner, Shyamala Maheswaran, Xin Hong, David Tomoaki Miyamoto, Tanya Todorova, Sarah Javaid
  • METHODS RELATING TO CIRCULATING TUMOR CELL CLUSTERS AND THE TREATMENT OF CANCER
    Publication number: 20240011035
    Abstract: Described herein are methods and assays relating to the presence and/or level of circulating tumor cells (CTCs). These CTC-Cs represent a highly metastatic subpopulation of CTCs. In some embodiments, the methods and assays described herein relate to the treatment of cancer.
    Type: Application
    Filed: July 13, 2022
    Publication date: January 11, 2024
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Nicola ACETO, Daniel Arie HABER, Shyamala MAHESWARAN
  • Digital Analysis of Blood Samples to Determine Efficacy of Cancer Therapies for Specific Cancers
    Publication number: 20220364185
    Abstract: This disclosure relates to new assay methods for analysis of RNA, e.g., from circulating tumor cells (CTCs), tumor-specific exosomes, or tumor-specific cell-free RNA, in a subject's blood sample to determine an expression level of one or more lineage markers in the blood sample, wherein the expression level of a specific one or more lineage markers is predictive of progression-free survival and overall survival for a specific anti-cancer treatment regimen in that subject.
    Type: Application
    Filed: May 27, 2022
    Publication date: November 17, 2022
    Inventors: Daniel Haber, Shyamala Maheswaran, Tanya Todorova, Mark Kalinich, David Tomoaki Miyamoto, Xin Hong
  • Methods relating to circulating tumor cell clusters and the treatment of cancer
    Patent number: 11421233
    Abstract: Described herein are methods and assays relating to the presence and/or level of circulating tumor cells (CTCs). These CTC-Cs represent a highly metastatic subpopulation of CTCs. In some embodiments, the methods and assays described herein relate to the treatment of cancer.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: August 23, 2022
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Nicola Aceto, Daniel Arie Haber, Shyamala Maheswaran
  • Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers
    Patent number: 11371101
    Abstract: This disclosure relates to new assay methods for analysis of RNA, e.g., from circulating tumor cells (CTCs), tumor-specific exosomes, or tumor-specific cell-free RNA, in a subject's blood sample to determine an expression level of one or more lineage markers in the blood sample, wherein the expression level of a specific one or more lineage markers is predictive of progression-free survival and overall survival for a specific anti-cancer treatment regimen in that subject.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: June 28, 2022
    Assignee: The General Hospital Corporation
    Inventors: Daniel Haber, Shyamala Maheswaran, Tanya Todorova, Mark Kalinich, David Tomoaki Miyamoto, Xin Hong
  • Biomarkers of Cancer
    Publication number: 20220098678
    Abstract: Methods for diagnosing cancer based on detecting the presence of increased levels of expression of satellite repeats and/or Line-1.
    Type: Application
    Filed: October 8, 2021
    Publication date: March 31, 2022
    Inventors: David Tsai Ting, Daniel A. Haber, Shyamala Maheswaran, Doron Lipson
  • Biomarkers of cancer
    Patent number: 11142800
    Abstract: Methods for diagnosing cancer based on detecting the presence of increased levels of expression of satellite repeats and/or Line-1.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: October 12, 2021
    Assignee: The General Hospital Corporation
    Inventors: David Tsai Ting, Daniel A. Haber, Shyamala Maheswaran, Doron Lipson
  • Diagnosis and monitoring treatment of prostate cancer
    Patent number: 11079383
    Abstract: Provided herein are assays and methods related to determining a ratio of expression levels of PSA/PSMA or determining the expression level of PSMA in circulating tumor cells for diagnosis and/or for the purpose of monitoring treatment efficacy for prostate cancers that are likely hormone resistant.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: August 3, 2021
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Daniel A. Haber, Shyamala Maheswaran, David T. Miyamoto
  • Digital Analysis of Circulating Tumor Cells in Blood Samples
    Publication number: 20210189501
    Abstract: This disclosure relates to new assay methods for analysis of circulating tumor cells (CTCs) in blood samples for detection, e.g., early detection, and/or monitoring of disease, e.g., cancer. The methods provide ultra-high sensitivity and specificity, and include the use of microfluidic isolation of CTCs and digital detection of RNA derived from the CTCs.
    Type: Application
    Filed: October 8, 2020
    Publication date: June 24, 2021
    Inventors: Daniel A. Haber, Ravi Kapur, Mehmet Toner, Shyamala Maheswaran, Xin Hong, David Tomoaki Miyamoto, Tanya Todorova, Sarah Javaid
  • METHODS AND ASSAYS RELATING TO CIRCULATING TUMOR CELLS
    Publication number: 20210130910
    Abstract: The technology described herein relates to methods of detecting circulating tumor cells (CTCs), e.g. by detecting changes in the expression of certain CTC marker genes. Aberrant expression of CTC marker genes, e.g. changes in expression indicative of CTCs can also be targeted in order to treat cancer.
    Type: Application
    Filed: November 23, 2020
    Publication date: May 6, 2021
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: David T. TING, Daniel A. HABER, Shyamala MAHESWARAN
  • Methods and assays relating to circulating tumor cells
    Patent number: 10900083
    Abstract: The technology described herein relates to methods of detecting circulating tumor cells (CTCs), e.g. by detecting changes in the expression of certain CTC marker genes. Aberrant expression of CTC marker genes, e.g. changes in expression indicative of CTCs can also be targeted in order to treat cancer.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: January 26, 2021
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: David T. Ting, Daniel A. Haber, Shyamala Maheswaran
  • LNA-based mutant enrichment next-generation sequencing assays
    Patent number: 10876151
    Abstract: Ultra-sensitive assays for the detection of mutations, e.g., from blood-based sources of tumor genetic material (circulating tumor cells or plasma), or other settings in which limiting amounts of DNA, e.g., tumor DNA, is available. The assay is exemplified in the estrogen receptor, but is broadly customizable to target mutations in other genes.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: December 29, 2020
    Assignee: The General Hospital Corporation
    Inventors: Tilak K. Sundaresan, Zongli Zheng, Daniel A. Haber, Shyamala Maheswaran, A. John Iafrate
  • METHODS RELATING TO CIRCULATING TUMOR CELL CLUSTERS AND THE TREATMENT OF CANCER
    Publication number: 20200392505
    Abstract: Described herein are methods and assays relating to the presence and/or level of circulating tumor cells (CTCs). These CTC-Cs represent a highly metastatic subpopulation of CTCs. In some embodiments, the methods and assays described herein relate to the treatment of cancer.
    Type: Application
    Filed: June 16, 2020
    Publication date: December 17, 2020
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Nicola ACETO, Daniel Arie HABER, Shyamala MAHESWARAN
  • Methods relating to circulating tumor cell clusters and the treatment of cancer
    Patent number: 10731162
    Abstract: Described herein are methods and assays relating to the presence and/or level of circulating tumor cells (CTCs). These CTC-Cs represent a highly metastatic subpopulation of CTCs. In some embodiments, the methods and assays described herein relate to the treatment of cancer.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: August 4, 2020
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Nicola Aceto, Daniel Arie Haber, Shyamala Maheswaran
  • TARGETING HUMAN SATELLITE II (HSATII)
    Publication number: 20200017856
    Abstract: Methods for treating cancer, e.g., cancer of epithelial origin, by specifically targeting human satellite II (HSATII) using sequence specific agents such as oligonucleotides.
    Type: Application
    Filed: April 24, 2019
    Publication date: January 16, 2020
    Inventors: David T. Ting, Daniel A. Haber, Shyamala Maheswaran, Francesca Bersani, Anders M. Naar, Mihir Shivadatta Rajurkar, Sakari Kauppinen, Andreas Petri
  • Digital Analysis of Blood Samples to Determine Efficacy of Cancer Therapies for Specific Cancers
    Publication number: 20190391134
    Abstract: This disclosure relates to new assay methods for analysis of RNA, e.g., from circulating tumor cells (CTCs), tumor-specific exosomes, or tumor-specific cell-free RNA, in a subject's blood sample to determine an expression level of one or more lineage markers in the blood sample, wherein the expression level of a specific one or more lineage markers is predictive of progression-free survival and overall survival for a specific anti-cancer treatment regimen in that subject.
    Type: Application
    Filed: October 27, 2017
    Publication date: December 26, 2019
    Inventors: Daniel Haber, Shyamala Maheswaran, Tanya Todorova, Mark Kalinich, David Tomoaki Miyamoto, Xin Hong
  • Targeting human satellite II (HSATII)
    Patent number: 10301624
    Abstract: Methods for treating cancer, e.g., cancer of epithelial origin, by specifically targeting human satellite II (HSATII) using sequence specific agents such as oligonucleotides. As shown herein, the hetero chromatic HSATII satellite repeat is silenced in normal cells, but massively over expressed in epithelial cancers and in cancer cell lines when grown as xenografts or in 3D culture. Induction of HSATII RNA, either in xenografts or using in vitro reconstitution models, suggests the appearance of complementary DNA intermediates.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: May 28, 2019
    Assignees: The General Hospital Corporation, Aalborg University
    Inventors: David T. Ting, Daniel A. Haber, Shyamala Maheswaran, Francesca Bersani, Anders M. Naar, Mihir Shivadatta Rajurkar, Sakari Kauppinen, Andreas Petri
  • METHODS RELATING TO CIRCULATING TUMOR CELL CLUSTERS AND THE TREATMENT OF CANCER
    Publication number: 20180320185
    Abstract: Described herein are methods and assays relating to the presence and/or level of circulating tumor cells (CTCs). These CTC-Cs represent a highly metastatic subpopulation of CTCs. In some embodiments, the methods and assays described herein relate to the treatment of cancer.
    Type: Application
    Filed: July 17, 2018
    Publication date: November 8, 2018
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Nicola ACETO, Daniel Arie HABER, Shyamala MAHESWARAN
  • Cadherins as cancer biomarkers
    Patent number: 10094837
    Abstract: Methods of isolating, enriching, capturing, identifying, or detecting the presence of, cancerous cells in a sample, e.g., a blood sample from a subject, by detecting the presence of one or more cancer cell surface markers selected from the group consisting of cadherin 1 (CDH1), CDH2, CDH3, CDH4, CDH5, CDH9, CDH11, CDH17, CDH19, protocadherin 9 (PCDH9) and/or PCDH beta 13 (PCDHb13), and optionally an additional cancer cell surface marker, e.g., EpCAM, MUC1, EphB4, EGFR, CEA, and/or HER2.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: October 9, 2018
    Assignee: The General Hospital Corporation
    Inventors: Shyamala Maheswaran, David Tsai Ting, Daniel A. Haber